CRG-023

About CARGO Therapeutics

CARGO Therapeutics is mission-driven to develop 'smarter' CAR T-cell therapies that deliver durable remissions for cancer patients who relapse after current cell therapies. Its core achievement is advancing CRG-022, a CD22-directed CAR T-cell therapy, into a pivotal Phase 2 trial for CD19 CAR T-refractory large B-cell lymphoma, a population with a dire prognosis. The company's strategy leverages a proprietary platform integrating switch technology and cytokine armoring to enhance T-cell fitness and overcome the immunosuppressive tumor microenvironment. CARGO aims to establish a new standard in cell therapy by systematically addressing the biological limitations of first-generation products.

Therapeutic Areas

Other Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NHL) Drugs